Whitepaper

Remdesivir in COVID-19
The leading COVID-19 antiviral drug - Remdesivir - proving its value in the treatment of severe as well as moderately affected patients
Remdesivir in COVID-19

More Whitepapers / Newsletters

Von Hippel-Lindau (VHL) syndrome Newsletter
Von Hippel-Lindau (VHL) syndrome

An inherited disorder, Von Hippel-Lindau (VHL) syndrome is characterized by the formation of tumors...

ASCO Reveals: Increasing Options for Relapse/ Refractory Patients in Haematological Malignancies Whitepaper
ASCO Reveals: Increasing Options for Relapse/ Refractory Patients in Haematological Malignancies

Immunotherapies, a potentially life-saving therapy, have benefitted several patients suffering from cancer help...

Cancer Globally (Vol. 1, Issue 1) Newsletter
Cancer Globally (Vol. 1, Issue 1)

Cancer has gripped the human society in its clutches in such a way that there has been many advancements to treat the same, but with little...

Hospital-acquired bacterial pneumonia/ Ventilator-associated bacterial pneumonia Newsletter
Hospital-acquired bacterial pneumonia/ Ventilator-associated bacterial pneumonia

Hospital-acquired bacterial pneumonia (HABP) is the most common type of health-care...

Current Treatment Challenges of IO Refractory Patients and Clinical Development of Therapies Targeting These Patients Whitepaper
Current Treatment Challenges of IO Refractory Patients and Clinical Development of Therapies Targeting These Patients

Over the years, the Oncology domain has experienced the entry of several treatment approaches. Therapeutic approaches such as surgery, radiation therapy...